Bio-Techne (TECH) Income from Non-Controlling Interests (2020 - 2022)
Bio-Techne's quarterly Income from Non-Controlling Interests came in at $179000.0 in Q3 2022, up 128.23% year-on-year from $78428.5 in Q3 2021, and down 54.22% quarter-over-quarter from $391000.0 in Q2 2022.
Bio-Techne has reported Income from Non-Controlling Interests for 3 years, with the latest figure at $179000.0 in Q3 2022.
- For the quarter ending Q3 2022, Income from Non-Controlling Interests rose 128.23% year-over-year to $179000.0; the trailing twelve-month figure through Jun 2023 stood at $179000.0 (up 102.0% YoY), and the FY2023 full-year result was $179000.0, up 102.0% from the prior year.
- Income from Non-Controlling Interests for Q3 2022 stood at $179000.0, down from $391000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was $391000.0 in Q2 2022, with the low at -$8.1 million in Q4 2021.
- Average Income from Non-Controlling Interests over 3 years is -$1.2 million, with a median of -$348000.0 recorded in 2021.
- Year-over-year, Income from Non-Controlling Interests slumped 6141.54% in 2021 and surged 223.73% in 2022.
- Tracing TECH's Income from Non-Controlling Interests over 3 years: stood at -$130000.0 in 2020, then tumbled by 6141.54% to -$8.1 million in 2021, then jumped by 102.21% to $179000.0 in 2022.
- The last three Income from Non-Controlling Interests figures came in at $179000.0 (Q3 2022), $391000.0 (Q2 2022), and -$595000.0 (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 179,000.00 |
| Jun 30, 2022 | 391,000.00 |
| Mar 31, 2022 | -595,000.00 |
| Dec 31, 2021 | -8.11 Mn |
| Sep 30, 2021 | -634,000.00 |
| Jun 30, 2021 | -316,000.00 |
| Mar 31, 2021 | -380,000.00 |
| Dec 31, 2020 | -130,000.00 |